RSV Vaccine for Older Adults Found Protective

GSK plc today announced new data from the AReSVi-006 phase III trial evaluating the efficacy of a single dose of AREXVY™ against lower respiratory tract disease caused by the respiratory syncytial virus (RSV) in adults aged 60 years and older over multiple RSV seasons and after annual revaccination.

The results presented on June 21, 2023, show that one dose of AREXVY is efficacious against RSV-LRTD and severe LRTD over two full RSV seasons.

In a press release, Tony Wood, Chief Scientific Officer of GSK, stated, "These data show the efficacy of a single dose of our vaccine over two RSV seasons against RSV-LRTD, including in the populations most at risk due to age or underlying medical conditions."

"This reinforces our confidence in its potential to make a significant public health impact."

"We look forward to discussing these results with regulators and vaccine recommending bodies and collecting more data from the ongoing clinical development program."

As of June 2023, there are two approved RSV vaccines for older people in the U.S.

UPDATE - The ACIP voted to recommend AREXVY on June 21, 2023.